Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Novavax (NVAX) Gains from Sales and Divestitures (2019 - 2020)

Novavax has reported Gains from Sales and Divestitures over the past 2 years, most recently at $781812.0 for Q3 2020.

Quarterly results put Gains from Sales and Divestitures at $781812.0 for Q3 2020, up 976.33% from a year ago — trailing twelve months through Sep 2020 was $781812.0 (up 976.33% YoY), and the annual figure for FY2019 was $72637.0, changed.
Gains from Sales and Divestitures for Q3 2020 was $781812.0 at Novavax, up from $47563.0 in the prior quarter.
Over the last five years, Gains from Sales and Divestitures for NVAX hit a ceiling of $781812.0 in Q3 2020 and a floor of $17563.0 in Q1 2020.